Shawnee, OK, United States of America

David Eugene Martin

USPTO Granted Patents = 4 

Average Co-Inventor Count = 6.8

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2018-2022

Loading Chart...
4 patents (USPTO):

Title: The Innovative Contributions of David Eugene Martin

Introduction

David Eugene Martin is a notable inventor based in Shawnee, Oklahoma, with a significant portfolio of four patents. His work primarily focuses on pharmaceutical innovations, particularly in the field of antiviral agents.

Latest Patents

One of Martin's latest patents involves triterpene amine derivatives. This invention concerns novel pharmaceutically active compounds that are useful as medicaments, particularly for the treatment of Human Immunodeficiency Virus-1 (HIV-1). The compounds are derivatives of betulinic acid, featuring specific substitutions that enhance their therapeutic efficacy. Another significant patent is related to C-3 novel triterpenone with C-28 urea derivatives. This invention also targets viral diseases, especially those mediated by HIV, and includes pharmaceutical compositions that utilize these innovative compounds.

Career Highlights

Throughout his career, Martin has worked with reputable companies such as Hetero Labs Limited and Dfh Therapeutics, Inc. His contributions to these organizations have been instrumental in advancing pharmaceutical research and development.

Collaborations

Martin has collaborated with notable professionals in the field, including Carl Thomas Wild and Theodore John Nitz. These partnerships have further enriched his work and expanded the impact of his inventions.

Conclusion

David Eugene Martin's innovative contributions to pharmaceutical science, particularly in the development of antiviral agents, highlight his significant role as an inventor. His patents reflect a commitment to addressing critical health challenges, particularly in the fight against HIV.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…